Wells Fargo & Company Ventyx Biosciences, Inc. Transaction History

Wells Fargo & Company

$434 Billion
Q3 2024

A detailed history of Wells Fargo & Company transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 33,402 shares of VTYX stock, worth $68,808. This represents 0.0% of its overall portfolio holdings.

Number of Shares

33,402

Previous 28,039 19.13%

Holding current value

$68,808

Previous $64,000 12.5%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$1.85 - $3.2 $9,921 - $17,161	5,363 Added 19.13%	33,402 $72,000
Q2 2024 Aug 13, 2024	BUY	$2.31 - $5.59 $30,117 - $72,882	13,038 Added 86.91%	28,039 $64,000
Q1 2024 May 10, 2024	BUY	$1.9 - $10.13 $5,266 - $28,080	2,772 Added 22.67%	15,001 $82,000
Q4 2023 Feb 09, 2024	SELL	$2.08 - $31.18 $37,972 - $569,222	-18,256 Reduced 59.89%	12,229 $30,000
Q3 2023 Nov 13, 2023	SELL	$29.8 - $40.3 $197,961 - $267,712	-6,643 Reduced 17.89%	30,485 $1.06 Million
Q2 2023 Aug 15, 2023	BUY	$28.53 - $39.55 $639,014 - $885,840	22,398 Added 152.06%	37,128 $1.22 Million
Q1 2023 May 12, 2023	BUY	$29.51 - $46.65 $375,219 - $593,154	12,715 Added 631.02%	14,730 $493,000
Q4 2022 Feb 13, 2023	SELL	$24.16 - $36.38 $52,644 - $79,272	-2,179 Reduced 51.96%	2,015 $66,000
Q3 2022 Nov 14, 2022	SELL	$12.64 - $38.7 $1,756 - $5,379	-139 Reduced 3.21%	4,194 $146,000
Q2 2022 Aug 12, 2022	BUY	$11.95 - $18.75 $23,469 - $36,825	1,964 Added 82.9%	4,333 $53,000
Q1 2022 May 16, 2022	SELL	$10.0 - $19.98 $37,370 - $74,665	-3,737 Reduced 61.2%	2,369 $32,000
Q4 2021 Feb 14, 2022	BUY	$14.2 - $23.07 $86,705 - $140,865	6,106 New	6,106 $121,000

Others Institutions Holding VTYX

# of Institutions

125

Shares Held

52.9M

Call Options Held

35.3K

Put Options Held

83K

View Full List

About Ventyx Biosciences, Inc.

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $116M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

More about VTYX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Ventyx Biosciences, Inc. Transaction History